Evolent Health (NYSE: EVH) insider transactions
In the twelve months to 10 November 2026, executives and directors of Evolent Health reported 1 open-market sale of 65,892 shares ($329,460) and 1 open-market purchase of 10,000 shares ($38,200), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 26 August 2026 | McCarthy Daniel Joseph | President | Open-market sale, 10b5-1 plan | −65,892 | $5.00 | 655,133 | Form 4 |
| 1 July 2026 | Shams Aammaad | Chief Accounting Officer | Grant or award | +28,790 | — | 95,637 | Form 4 |
| 1 July 2026 | McCarthy Daniel Joseph | President | Grant or award | +302,585 | — | 725,607 | Form 4 |
| 1 July 2026 | McCarthy Daniel Joseph | President | Shares withheld for tax | −4,582 | $5.74 | 721,025 | Form 4 |
| 1 July 2026 | Blackley Seth | Chief Executive Officer | Grant or award | +446,102 | — | 1,283,064 | Form 4 |
| 1 July 2026 | Blackley Seth | Chief Executive Officer | Shares withheld for tax | −10,297 | $5.74 | 1,272,767 | Form 4 |
| 1 July 2026 | Weinberg Jonathan | General Counsel | Grant or award | +43,055 | — | 287,567 | Form 4 |
| 1 July 2026 | Weinberg Jonathan | General Counsel | Shares withheld for tax | −2,650 | $5.74 | 284,917 | Form 4 |
| 4 June 2026 | Barbarosh Craig A. | Director | Grant or award | +41,096 | — | 95,031 | Form 4 |
| 4 June 2026 | Springstubb Brendan B | Director | Grant or award | +41,096 | — | 99,917 | Form 4 |
| 4 June 2026 | Smith Jill D. | Director | Grant or award | +41,096 | — | 64,233 | Form 4 |
| 4 June 2026 | Keck Kim | Director | Grant or award | +41,096 | — | 102,597 | Form 4 |
| 4 June 2026 | Jelinek Richard M | Director | Grant or award | +41,096 | — | 77,533 | Form 4 |
| 4 June 2026 | Guertin Shawn M | Director | Grant or award | +41,096 | — | 63,075 | Form 4 |
| 4 June 2026 | Grua Peter J | Director | Grant or award | +41,096 | — | 63,075 | Form 4 |
| 4 June 2026 | Glass Russell Monroe | Director | Grant or award | +41,096 | — | 77,347 | Form 4 |
| 4 June 2026 | Ajayi Toyin | Director | Grant or award | +41,096 | — | 75,170 | Form 4 |
| 3 March 2026 | Shams Aammaad | Chief Accounting Officer | Shares withheld for tax | −4,311 | $3.51 | 66,847 | Form 4 |
| 3 March 2026 | McCarthy Daniel Joseph | President | Shares withheld for tax | −24,027 | $3.51 | 423,022 | Form 4 |
| 3 March 2026 | Blackley Seth | Chief Executive Officer | Shares withheld for tax | −24,053 | $3.51 | 836,962 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Evolent Health page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.